psalexa
logo

Cushing’s Syndrome Therapeutics Pipeline Analysis

Cushing’s Syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS10981
Available Format:

The expending growth of pipeline for Cushing’s syndrome therapeutics is attributed to the increase in prevalence of inflammatory disorders. For the treatment of various inflammatory disorders patients use corticosteroids, the long-term use of corticosteroids can lead to Cushing’s syndrome. In many diseases such as asthma and rheumatoid arthritis, corticosteroids are being used, for a lifelong period but at low doses. However, when the disease fails to respond to lower doses of corticosteroids, the dose needs to be increased. The pipeline for Cushing’s syndrome is majorly driven by factors such as, increasing healthcare awareness in patients and the occurrence of abnormal growth of cells in pituitary gland which can further lead to the formation of tumour.

Cushing’s syndrome is a condition that occurs when a person is exposed to the hormone cortisol at a very high level, for a longer period of time, this is sometimes called as hypercortisolism. It mostly affects obese people at the aged between 20 to 50 years, who have type 2 diabetes and high blood pressure. The symptoms of the Cushing’s syndrome, include, round face, upper body obesity, deposition of fat around neck and relatively lean arms and legs. In some cases, skin of the patients become fragile, heals poorly, bruises easily and purple or pink marks appear on the abdomen, buttocks, thigh and breast. Bones become weakened and spinal and column fracture can occur when person is doing any routine activity like bending, lifting etc. Other symptoms include severe fatigue, increased thirst and urination, irritability, anxiety, depression and weak muscles.

Corcept Therapeutics is introducing a drug names, CORT125134, GRII receptor antagonist with potential antineoplastic activity which is currently in Phase II stage of clinical development. CORT125134 binds competitively to GRII receptor and prevents the translocation of ligand bind complexes to nucleus for the expression of GR-associated genes. Strongbridge Biopharma Plc plans to introduce a drug by the name COR-003, which is a single enantiomer od ketoconazole with data reflecting the improvement of its therapeutic index as compared to ketoconazole. COR-003 is presently being inspected in Phase III study for the treatment of endogenous Cushing’s syndrome. Millendo Therapeutics, Inc. is in the process of introducing a drug ATR-101 which selectively targets the acyl-CoA: cholesterol acyltransferase 1 enzyme that causes the transformation of free cholesterol to cholesterol ester. Cholesterol ester servez as a reservoir of synthesis of steroids.

In April 2012, Strongbridge Biopharma Plc was in the process of collaboration with Moulder Center Drug Discovery for the development of new therapies of cortisol modulation for Cushing syndrome therapeutics. In July 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. announced that the companies are undergoing a strategic immuno-oncology collaboration in Japan, South Korea and Taiwan, which includes the development and commercialization of immune mediated endocrinopathies. In September 2008, Corcept Therapeutics and Eli Lilly and Company announced that the companies would continue the collaboration for testing the effectiveness of GRII receptor antagonist in rat models of olanzapine induced weight gain.

Some of the companies having a pipeline of Cushing’s syndrome therapeutics include Corcept Therapeutics, Millendo Therapeutics, Inc., Strongbridge Biopharma Plc, Novartis AG. Ono Pharmaceutical Co., Ltd. Bristol-Myers Squibb Company.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry